Key takeaway: The investor presentation by Dishman Carbogen Amcis Limited reported on the unaudited financial results for the quarter ended June 30, 2026. Net revenue was ₹6,776 million, a decrease of 4.3% from ₹7,080 million in the same quarter of the previous year, primarily due to a decline in CDMO revenue, which fell by 12.6% year-over-year. The Marketable Molecules segment, however, saw a significant increase of 48%, driven by higher cholesterol revenue. EBITDA margin decreased to 8.9% from 19.9% year-over-year, attributed to fixed costs amid deferred revenues and a foreign exchange loss. The presentation highlighted a strong pipeline with 13 molecules in late Phase III development and emphasized the company's integrated capabilities across the value chain in the CDMO sector. The document also provided insights into the company's global presence and strategic partnerships.

Key takeaway: During the earnings conference call on May 20, 2026, Dishman Carbogen Amcis Limited reported a revenue of INR 851 crores for Q4 FY26, reflecting a 19% growth year-over-year. The CDMO segment saw a 21% increase in revenue, while the marketable molecules segment grew by 9.3%. Management highlighted strong performance in Vitamin D analogs and late-phase projects, with over 30 commercial products contributing to revenue. Cost-control measures were implemented, and employee expenses rose due to a pension plan switch. The company achieved an EBITDA of INR 163 crores, with a margin of 19.1%. For the full fiscal year, revenue reached INR 2,932 crores, an 8% increase, and profit after tax was INR 97.4 crores. Management expressed optimism about future growth, particularly in the Indian market, and discussed plans for a long-term external commercial borrowing to reduce high-cost debt in India.

Key takeaway: The investor presentation by Dishman Carbogen Amcis Limited, dated May 20, 2026, provided an overview of the company's audited financial results for the quarter and year ended March 31, 2026. The presentation highlighted a net revenue increase to ₹8,514 million in Q4FY26, up 18.9% from ₹7,163 million in Q4FY25, driven by growth in both the CDMO and Marketable Molecules segments. For FY26, net revenue reached ₹29,319 million, an 8.1% increase from ₹27,115 million in FY25. EBITDA for Q4FY26 was reported at ₹1,630 million with a margin of 19.1%, while FY26 EBITDA was ₹5,656 million, reflecting a margin of 19.3%. The document also noted a focus on late-phase III molecules and an increase in capacity utilization. Additionally, the company reported a net debt of CHF 146.80 million as of March 31, 2026, down from CHF 157.6 million the previous year.

Key takeaway: The investor presentation by Dishman Carbogen Amcis Limited, dated February 4, 2026, provided an overview of the company's unaudited financial results for the third quarter ended December 31, 2025. The presentation reported a net revenue of ₹7,198 million for Q3FY26, reflecting a 5.5% year-over-year increase from ₹6,823 million in Q3FY25, primarily driven by higher revenue from the CDMO segment. EBITDA for Q3FY26 was reported at ₹1,131 million, with an EBITDA margin of 15.7%, down from 20.5% in the previous year. The document highlighted a deferred revenue of approximately ₹20 crore from Q3FY26 to Q4FY26 due to supply delays. The presentation also noted the company's focus on improving capacity utilization and expanding its market presence, particularly in the oncology segment, with 12 molecules in phase III development. Overall, the document emphasized the company's integrated CDMO capabilities and ongoing digital transformation initiatives.